SavedAdd your journal

Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2020 / Cilt: 73 - Sayı: 2

Investigation of Molecular Changes in RAS/RAF/MEK/MAPK Pathway in Serous Adenocarcinomas and Serous Borderline Tumors of Ovary

Overin Seröz Adenokarsinomları ve Seröz Borderline Tümörlerinde RAS/RAF/MEK/MAPK Yolağındaki Moleküler Değişikliklerin Araştırılması

Cevriye CANSIZ ERSÖZ
Pages
144–148
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: In borderline and benign lesions, diffuse and severe staining was observed in all cases with c-Fos, whereas focal and mild staining was observed in only 16 of the serous adenocarcinomas (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To investigate MAP Kinase (p38), c-Fos, c-Jun and c-Myc; in RAS/RAF/MEK/MAPK pathway by immunohistochemically in high grade serous adenocarcinomas, serous borderline tumors and benign lesions of the ovary.
📊
Key Findings & Data:Materials and Methods: Twelve serous borderline tumors, 41 high-grade serous carcinomas and 19 cases of serous papillary cystadenofibromas, serous cystadenomas; p38, c-Myc, c-Jun and c-Fos immunohistochemical staining were performed.
💡
Conclusion & Impact:Results: In borderline and benign lesions, diffuse and severe staining was observed in all cases with c-Fos, whereas focal and mild staining was observed in only 16 of the serous adenocarcinomas (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To investigate MAP Kinase (p38), c-Fos, c-Jun and c-Myc; in RAS/RAF/MEK/MAPK pathway by immunohistochemically in high grade serous adenocarcinomas, serous borderline tumors and benign lesions of the ovary. Materials and Methods: Twelve serous borderline tumors, 41 high-grade serous carcinomas and 19 cases of serous papillary cystadenofibromas, serous cystadenomas; p38, c-Myc, c-Jun and c-Fos immunohistochemical staining were performed. Results: In borderline and benign lesions, diffuse and severe staining was observed in all cases with c-Fos, whereas focal and mild staining was observed in only 16 of the serous adenocarcinomas (p

Özet

Amaç: Overin yüksek dereceli seröz adenokarsinomları, seröz borderline tümörleri ve benign lezyonlarında RAS/RAF/MEK/MAPK yolağında değişikbasamaklarda olduğu bildirilen moleküller; MAP Kinaz (p38), c-Fos, c-Jun ve c-Myc’in immünhistokimyasal olarak araştırılması amaçlanmıştır.Gereç ve Yöntem: On iki seröz borderline tümör, 41 yüksek dereceli seröz karsinom ve seröz papiller kistadenofibrom, seröz kistadenomlardan oluşan19 olgu ile birlikte, toplam 72 olgu üzerinde p38, c-Myc, c-Jun ve c-Fos immünhistokimyasal boyamaları yapılmıştır.Bulgular: c-Fos ile bordeline ve benign lezyonlarda olguların tamamında yaygın ve şiddetli boyanma izlenirken, seröz adenokarsinomların yalnızca16’sında fokal ve hafif boyanma izlenmiştir (p

🔖

Cite This Article

ERSÖZ, C. C. (2022). Investigation of Molecular Changes in RAS/RAF/MEK/MAPK Pathway in Serous Adenocarcinomas and Serous Borderline Tumors of Ovary. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 73 - Sayı: 2, 144–148. https://ajindex.com/articles/443522

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. ShihIe M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511- 1518
  2. Kurman RJ, Carcangiu ML, Herrington S, Young RH eds 4. IARC; Lyon, France: 2014. WHO classification of tumours of female reproductive organs 3. Kurman RJ, ShihIe M. The Dualistic Model of Ovarian Carcinogenesis; Revisited, Revised, and Expanded. Am J Pathol. 2016;186: 733-747
  3. Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Nat Cancer Inst. 2003;95:484-486
  4. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in lowgrade and high-grade carcinomas. Cancer Res. 2009;69:4036-4042
  5. Pohl G, Ho CL, Kurman RJ, et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res. 2005;65:1994- 2000
  6. Kurman RJ, Vang R, Junge J, et al. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol. 2011;35:1605-1614
  7. Jones S, Wang TL, Kurman RJ, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012;226:413-420
  8. Howitt BE, Hanamornroongruang S, Lin DI, et al. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol. 2015;39:287-293
  9. Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489- 494
  10. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456
  11. Finch A, Beiner M, Lubinski J, et al. Hereditary Ovarian Cancer Clinical Study Group Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-192
  12. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236
  13. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101:4667-4679
  14. Cuadrado A,